Zepbound vs Mounjaro: What's the Difference?

“Is Zepbound just Mounjaro with a different name?” It is one of the first questions people ask once they hear that both shots contain tirzepatide. The short answer: same active ingredient, same doses, different products. The longer answer matters, because the differences decide who each one is approved for, whether a prescription is on-label or off-label, and how your insurance is likely to treat it.

This guide compares the two side by side using the current US prescribing information for each product (both revised in August 2026), FDA announcements and NIH guidance. If you are new to the drug itself, start with what is tirzepatide? or the broader explainer on what a GLP-1 medication is.

Educational only. This is not medical advice. Do not start, stop, switch or change the dose of any medication without guidance from a licensed clinician who knows your history.

The direct answer

Zepbound and Mounjaro are both brand names for tirzepatide, a once-weekly injection made by Eli Lilly that activates two gut-hormone receptors, GIP and GLP-1. The molecule is the same, and so are the strengths. What differs is:

• The approved use. Mounjaro is approved for type 2 diabetes (blood sugar control, plus lowering heart-attack, stroke and cardiovascular-death risk in adults with type 2 diabetes who are at high risk). Zepbound is approved for chronic weight management in adults with obesity, or overweight plus a weight-related health problem, and for moderate to severe obstructive sleep apnea in adults with obesity.
• Who it is for. Mounjaro can be used in children 10 and older with type 2 diabetes. Zepbound is for adults only.
• The paperwork. Prescribing Mounjaro purely for weight loss is off-label, and insurance plans often cover the two very differently.

Everything else, from how they work to the dose steps and most of the safety information, is nearly identical, because it is the same drug.

Why one drug has two brand names

US drug approvals are tied to specific uses. Tirzepatide was first approved in 2022 as Mounjaro, to be used with diet and exercise to improve blood sugar in adults with type 2 diabetes. Lilly then ran a separate set of large trials testing tirzepatide specifically for weight loss in people with obesity or overweight, with and without diabetes.

Those trials led to a separate approval under a separate name. On November 8, 2023, the FDA approved Zepbound for chronic weight management, noting in its announcement that tirzepatide “is already approved under the trade name Mounjaro” for blood sugar in type 2 diabetes. A year later, on December 20, 2024, the FDA added a second Zepbound use: moderate to severe obstructive sleep apnea in adults with obesity, which the agency described as the first drug treatment option for certain patients with the condition.

Giving the weight-management product its own brand keeps each label focused on the uses that were actually studied and approved for it. If this pattern sounds familiar, it is: semaglutide works the same way, with Ozempic for diabetes and Wegovy for weight. Our guide to Wegovy vs Ozempic covers that pair.

Approved uses, side by side

Here is what each US label currently lists. “Approved for” means the FDA reviewed evidence for that specific use.

	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Form	Once-weekly injection	Once-weekly injection
Blood sugar control	Adults and children 10 and older with type 2 diabetes (with diet and exercise)	Not an approved use
Weight reduction and long-term maintenance	Not an approved use	Adults with obesity, or overweight plus at least one weight-related condition (with a reduced-calorie diet and more physical activity)
Obstructive sleep apnea	Not an approved use	Moderate to severe OSA in adults with obesity
Heart-risk reduction	Adults with type 2 diabetes at high risk of major cardiovascular events	Not an approved use
Age	Adults; children 10 and older (max 10 mg weekly)	Adults only
Maximum adult dose	15 mg once weekly	15 mg once weekly

Mounjaro’s heart indication is the newest change: it was added to the label in August 2026, based on a large trial called SURPASS-CVOT. That trial compared tirzepatide with dulaglutide, another diabetes medicine already approved for heart-risk reduction, in about 13,300 adults with type 2 diabetes and established heart disease. Over a median of about four years, tirzepatide was non-inferior to dulaglutide for heart attack, stroke or cardiovascular death (12.1% vs 13.0% had an event). “Non-inferior” means it was shown to be at least about as good; the label states superiority to dulaglutide was not established. Note that the comparison was against another active heart-protective drug, not a placebo.

How they work (the same way)

Because the active ingredient is identical, the mechanism is identical. Tirzepatide mimics two hormones your gut releases after you eat, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). The FDA describes Zepbound as activating these receptors “to reduce appetite and food intake.” The Mounjaro label notes that tirzepatide lowers fasting and after-meal blood sugar, decreases food intake and reduces body weight.

Cleveland Clinic summarizes the everyday effect: tirzepatide signals your brain when you are full, reduces hunger and food cravings, and slows digestion, so you stay fuller for longer. For most people, the result is eating less without as much of a fight against appetite. For more on the biology, see how GLP-1 medications work for weight loss.

Doses, pens and vials: almost identical

This is where Zepbound and Mounjaro differ least. Both labels list the same strengths and the same pattern of slow increases. The schedules below are the label’s standard pattern, shown so you can see how the products compare. Your actual plan, including whether to move up, stay put or step back, is set by your prescriber.

Shared pattern (both products)

• Start at 2.5 mg once weekly for 4 weeks. This is a starter dose to let your digestive system adjust, not a treatment dose.
• Increase in 2.5 mg steps, only after at least 4 weeks on the current dose.
• Available strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg.
• Maximum: 15 mg once weekly in adults.

Where the labels differ

• Zepbound names target maintenance doses: 5, 10 or 15 mg weekly for weight reduction and maintenance, and 10 or 15 mg for sleep apnea. The label says to consider both response and tolerability when choosing, and to consider a lower maintenance dose if a higher one is not tolerated.
• Mounjaro says to raise the dose only if more blood sugar control is needed. Children 10 and older with type 2 diabetes top out at 10 mg.

Same practical rules. Both are injected under the skin of the belly or thigh, or by someone else in the back of the upper arm, once a week at any time of day, with or without food. Rotate the injection spot each week. Both labels give the same missed-dose rule: take it as soon as possible within 4 days (96 hours); if more than 4 days have passed, skip it and take the next dose on your usual day. You can change your injection day as long as doses are at least 3 days (72 hours) apart.

Four ways the medicine can come

Both products are now sold in the same four presentations:

1. Single-dose pens (one dose each, needle built in).
2. Single-dose vials, used with a new syringe and needle each time.
3. Multi-dose vials holding four doses.
4. Single-patient-use KwikPens holding four doses.

Both labels added the same warning in January 2026: never share a KwikPen between people, even if the needle is changed. Both also say the KwikPen is not recommended for self-injection by people with visual impairment. If your prescription switches from pens to vials or the other way round, the label asks your care team to retrain you on the new device, so ask for that. Our tirzepatide hub gathers our guides on dosing and devices as they are published.

Weight loss: what the trials show

This is where people often compare numbers that were never meant to be compared. Mounjaro’s trials were designed to measure blood sugar in people with type 2 diabetes, usually over 40 to 52 weeks; weight was a secondary result. Zepbound’s trials were designed to measure weight loss, over 72 weeks, alongside a reduced-calorie diet and more physical activity.

From the current labels:

Trial (from the label)	Who	Dose	Length	Average weight change
Mounjaro SURPASS-1	Adults with type 2 diabetes, average BMI 32	5 / 10 / 15 mg	40 weeks	−6.3 / −7.0 / −7.8 kg vs −1.0 kg on placebo
Mounjaro SURPASS-2	Adults with type 2 diabetes on metformin	5 / 10 / 15 mg vs semaglutide 1 mg	40 weeks	−7.6 / −9.3 / −11.2 kg vs −5.7 kg on semaglutide 1 mg
Zepbound Study 1	Adults with obesity, or overweight plus a condition, without diabetes	5 / 10 / 15 mg	72 weeks	−15.0% / −19.5% / −20.9% vs −3.1% on placebo
Zepbound Study 2	Adults with type 2 diabetes and BMI 27 or higher	10 / 15 mg	72 weeks	−12.8% / −14.7% vs −3.2% on placebo

Three things stand out:

1. Longer treatment with weight as the goal shows larger losses. In Zepbound Study 1, 85% to 91% of people on tirzepatide lost at least 5% of their body weight (34.5% on placebo), and about half or more of those on 10 or 15 mg lost at least 20%.
2. People with type 2 diabetes tend to lose less on the same drug. Compare Zepbound Study 1 (up to −20.9%) with Study 2 (up to −14.7%), both over 72 weeks.
3. These are averages. Individual results range widely, and in the weight trials, between about 5% and 7% of people stopped treatment because of side effects, compared with 3.4% on placebo.

One more trial is worth knowing about. In Zepbound Study 4, people who had lost an average of 20.9% over 36 weeks were randomly split: those who kept taking tirzepatide lost a further 5.5% over the next year, while those switched to placebo regained 14.0%. That is a strong hint that the effect lasts only as long as treatment does, which is true of both brands. See why weight loss plateaus happen for what happens to appetite and energy use over time.

Sleep apnea: an approval only Zepbound has

Obstructive sleep apnea (OSA) happens when the upper airway keeps getting blocked during sleep, causing pauses in breathing. It is more common in people with overweight or obesity. Zepbound is approved to treat moderate to severe OSA in adults with obesity, alongside a reduced-calorie diet and more physical activity.

The approval rests on two 52-week trials in 469 adults without type 2 diabetes, one in people already using positive airway pressure (PAP, the standard treatment, such as a CPAP machine) and one in people unable or unwilling to use it. In the label:

• Breathing disruptions (the apnea-hypopnea index, or AHI) fell by about 25 to 29 events per hour on tirzepatide, versus about 5 events per hour on placebo.
• Roughly 42% to 50% of people on tirzepatide reached remission or mild OSA without symptoms, versus about 14% to 16% on placebo.
• Average weight loss was 17.7% to 19.6%, versus about 2% on placebo.

The FDA notes that the improvement in breathing is likely related to the weight reduction. Two practical points: the approved OSA maintenance dose is 10 or 15 mg, and Zepbound is meant to be used with, not instead of, care from a sleep specialist. Do not stop using a CPAP machine without talking to the clinician who prescribed it.

Mounjaro has no OSA indication. Someone with type 2 diabetes and sleep apnea may therefore end up on either product depending on which condition is driving the prescription and what their plan covers.

Side effects and safety: nearly identical

Since both products contain tirzepatide, their safety information overlaps almost entirely.

Most common side effects (both labels): nausea, diarrhea, vomiting, constipation, indigestion and abdominal pain. The Zepbound label also lists injection-site reactions, fatigue, allergic-type reactions, burping, hair loss and reflux among its common reactions; the Mounjaro label lists decreased appetite. In both labels, most nausea, vomiting and diarrhea happened while the dose was being raised and eased over time. Practical help is in our guides to GLP-1 nausea and constipation and diarrhea on GLP-1s.

Why the percentages look different. In Zepbound’s weight trials, nausea affected 25% to 29% of people on tirzepatide (8% on placebo). In Mounjaro’s diabetes trials, it affected 12% to 18% (4% on placebo). That does not mean one brand is gentler. The trials enrolled different people, lasted different lengths of time and counted side effects in different pools, so the figures are not a head-to-head comparison. You will also see posts claiming the GIP part of tirzepatide “blunts” nausea and makes it far easier to tolerate than other GLP-1s; neither label makes that claim, and digestive side effects are the most common problem in both.

Same boxed warning. Both carry a boxed warning that tirzepatide caused thyroid C-cell tumors in rats; it is unknown whether it causes them in humans. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), and in people with a serious allergy to tirzepatide or the product’s ingredients.

Shared warnings and precautions include:

• Severe digestive reactions; neither is recommended for people with severe gastroparesis.
• Acute kidney injury from dehydration after vomiting or diarrhea.
• Gallbladder problems such as gallstones.
• Acute pancreatitis (stop and seek care if it is suspected, for example with severe belly pain that may spread to the back).
• Serious allergic reactions, including anaphylaxis and angioedema.
• Low blood sugar, especially when combined with insulin or a sulfonylurea.
• Worsening diabetic eye disease in people who already have diabetic retinopathy.
• Risk of breathing food into the lungs during anesthesia or deep sedation, so tell your care team about any planned procedure.

Birth control pills. Both labels advise people on oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase, because tirzepatide slows stomach emptying.

Pregnancy. The Zepbound label says weight loss offers no benefit during pregnancy and to stop the medicine once a pregnancy is recognized. The Mounjaro label, written for people with diabetes, says it should be used in pregnancy only if the potential benefit justifies the potential risk. Cleveland Clinic notes tirzepatide can stay in your system for about four weeks after the last dose, so plan ahead with your clinician.

Never take them together. Both labels say tirzepatide should not be combined with another tirzepatide-containing product or with any GLP-1 receptor agonist. Doubling up raises the risk of side effects without a proven benefit.

On-label vs off-label: why it matters for you

A clinician can legally prescribe an approved medicine for a use that is not on its label. That is called off-label prescribing, and it is common across medicine. NIDDK, part of the NIH, explains that off-label use for weight can mean a drug approved for a different medical problem, and that you should feel comfortable asking whether your clinician is prescribing a medicine that is not approved for treating overweight and obesity. NIDDK also notes that tirzepatide is FDA-approved for type 2 diabetes “under a different name,” Mounjaro.

For Mounjaro, weight loss alone is off-label. In practical terms:

• The evidence base is different. Zepbound’s dosing and safety for weight management were tested in people with obesity or overweight, with and without diabetes. Mounjaro’s label was built on studies in people with type 2 diabetes.
• The instructions are framed differently. Mounjaro’s dose goes up for blood sugar control; Zepbound’s dose is chosen for weight response and tolerability.
• Coverage can differ. Insurers decide coverage by plan, and many tie it to an approved diagnosis.

If you have type 2 diabetes and overweight or obesity, either product may be on the table, and the choice depends on your goals, other conditions, other medicines and coverage. If you do not have diabetes, Zepbound is the tirzepatide product approved for weight management. Our guide to who qualifies for GLP-1 weight-loss treatment explains the BMI and health criteria.

Insurance, cost and why the label matters

List prices, savings programs and cash-pay options change often, so we keep the numbers in one place: the GLP-1 costs hub. A few principles hold steady:

• NIDDK notes that some, but not all, insurance plans cover medicines that treat overweight and obesity. Call your plan and ask about the specific product, its formulary tier, and whether prior authorization is required.
• Coverage of Mounjaro usually depends on a type 2 diabetes diagnosis. A plan that covers it for diabetes may not cover it for weight loss.
• Zepbound has two approved uses. Coverage can depend on which diagnosis is on the prescription (weight management or sleep apnea), so ask your plan specifically which uses it covers.
• Paying cash for either product does not change its approved use or safety rules.

When you call, have the product name, the strength and the diagnosis your clinician is using ready. Our step-by-step guide on how to get a GLP-1 prescription covers prior authorization and what to bring to the visit.

Shortages, compounded versions and fakes

During the shortage years, many people were offered compounded tirzepatide. The FDA first announced that the tirzepatide injection shortage, which began in 2022, was resolved on October 2, 2024, re-evaluated that decision during litigation, and confirmed it on December 19, 2024. The agency then gave compounders a transition period: until February 18, 2025, for state-licensed pharmacies, and until March 19, 2025, for outsourcing facilities, to stop making copies that had been allowed only because of the shortage.

Two points from FDA are worth knowing:

• Compounded drugs are not FDA-approved. FDA says unapproved versions of GLP-1 drugs, including tirzepatide, do not undergo its review for safety, effectiveness and quality before they are marketed.
• Get medicines from a licensed pharmacy. FDA has warned about counterfeit GLP-1 drugs sold in the US (such as counterfeit Ozempic), which may contain the wrong ingredient, the wrong amount, or none at all.

Compounded products are neither “generic Zepbound” nor “generic Mounjaro.” Our guide to how telehealth weight-loss programs work lists FDA’s red flags for online sellers.

Common myths, corrected

“Zepbound and Mounjaro are exactly the same, so it doesn’t matter which one you get.” The molecule and doses are the same, but the approved uses, age ranges, insurance treatment and on-label status are not. Those differences are practical.

“Zepbound is the stronger one.” It is the same drug in the same strengths with the same 15 mg ceiling. Zepbound’s trial numbers look bigger because those trials were longer, aimed at weight, and included many people without diabetes.

“Mounjaro’s heart approval proves it prevents heart attacks better than other diabetes drugs.” SURPASS-CVOT compared tirzepatide with another active diabetes drug, dulaglutide, and showed it was non-inferior. Superiority was not established.

“The GIP part makes tirzepatide nausea-free.” Nausea and other digestive effects are the most common side effects in both labels, and they are the main reason people stop. The slow step-up exists for this reason.

“Since it’s one drug, you can use leftover Mounjaro with a new Zepbound prescription.” Do not combine or swap products on your own. Both labels say not to use tirzepatide with another tirzepatide product, and dose or device changes should come from your prescriber and pharmacist.

How to decide, with your clinician

This is a decision for you and a licensed clinician who knows your history. These questions can make the conversation more productive:

1. Do I have type 2 diabetes, prediabetes, sleep apnea, heart disease or kidney disease, and does that change which product fits?
2. Is the product you are suggesting being used on-label or off-label for me?
3. Pen, KwikPen or vial? What does each routine involve, and who will train me?
4. What maintenance dose will we aim for, and how will we handle nausea or other side effects during the step-up?
5. Do any of my current medicines (especially insulin, sulfonylureas or birth control pills) need adjusting?
6. What will my plan cover, under which diagnosis, and is prior authorization needed?
7. How will we protect muscle while I lose weight? (See how much protein you need on a GLP-1, what to eat on a GLP-1 and strength training on GLP-1s.)
8. What is the long-term plan if the medicine works, or if it does not?

Where semaglutide fits

People comparing Zepbound and Mounjaro often hear about Wegovy and Ozempic too. Those brands contain a different drug, semaglutide, which activates only the GLP-1 receptor, and the same “one drug, two brands” logic applies: Ozempic for type 2 diabetes, Wegovy for weight management. Mounjaro’s own label includes one direct comparison: in SURPASS-2, tirzepatide at 5, 10 and 15 mg lowered blood sugar and weight more than semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. That trial used an Ozempic-level dose, not the higher Wegovy weight-loss dose, so it does not settle which is better for weight management. Read more in what is semaglutide?, Wegovy vs Ozempic and our semaglutide vs tirzepatide guide. For the full list of medicines with a weight-management approval, see which GLP-1s are FDA-approved for weight loss.

The bottom line

Zepbound and Mounjaro are the same medicine, tirzepatide, in the same once-weekly strengths, packaged and approved for different jobs. Mounjaro treats type 2 diabetes in adults and children 10 and older and, since August 2026, is approved to lower heart risk in adults with type 2 diabetes at high risk. Zepbound is the tirzepatide product approved for weight reduction and long-term maintenance in adults, and for moderate to severe sleep apnea in adults with obesity. Their side effects and safety warnings are nearly identical. The right choice depends on your diagnosis, goals, other medicines and coverage, and it should be made with a clinician, not by swapping products or doses on your own.

Explore more in the tirzepatide hub and the GLP-1 Guide hub.